This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 3 EPO patents. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
Title: **Yinyan Zhao: Innovator in mTOR Inhibition**
Introduction
Yinyan Zhao is an accomplished inventor based in Rockville, Maryland. He holds a significant patent that showcases his expertise in medicinal chemistry, particularly in the inhibition of the mTOR pathway, which is vital in various diseases.
Latest Patents
Yinyan Zhao is credited with a patent for "Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors." This innovative invention provides methods for inhibiting mTOR by utilizing pyrazolo[1,5-a]pyrimidine compounds. These compounds are instrumental in the treatment, prevention, inhibition, or amelioration of diseases associated with mTOR, highlighting the potential therapeutic applications of his work.
Career Highlights
Yinyan Zhao has made a notable impact in the pharmaceutical sector, primarily through his work at Merck Sharp & Dohme Corporation. His contributions have advanced the understanding and potential treatments available for mTOR-related diseases. The patent he holds underscores his dedication to the field and the innovative approaches he has pioneered.
Collaborations
Throughout his career, Yinyan has collaborated with esteemed colleagues such as Yongqi Deng and Binyuan Sun. Their joint endeavors emphasize the importance of teamwork in driving innovation and enhancing research outcomes in the pharmaceutical industry.
Conclusion
Yinyan Zhao stands out as a key figure in the realm of mTOR inhibition, bringing valuable innovations to the forefront of medical research. His work not only reflects his expertise but also highlights the collaborative spirit necessary for breakthroughs in science and medicine. With his patent and ongoing contributions, Yinyan continues to influence the future of therapeutic development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
